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Objectives. The aims of this study were to describe the incidence
and spectrum of thromboembolic events experienced by patients
with moderate to severe left ventricular systolic dysfunction in
normal sinus rhythm and to study the association between
ejection fraction and thromboembolic risk.
Background. The annual incidence of thromboembolic events in
patients with heart failure is estimated to range from 0.9% to
5.5%. Previous studies demonstrating a relation between worsen-
ing left ventricular systolic function and thromboembolic risk are
difficult to interpret because of the prevalence of atrial fibrillation,
an independent risk factor for thromboembolism, in the patients
with a lower ejection fraction.
Methods. This is a retrospective analysis of the Studies of Left
Ventricular Dysfunction prevention and treatment trials data
base. Patients with atrial fibrillation were excluded, resulting in
6,378 participants in sinus rhythm at the time of randomization.
Thromboembolic events include strokes, pulmonary emboli and
peripheral emboli. Separate analyses were conducted in each
gender because there was evidence of a significant interaction
between ejection fraction and gender on the risk of thromboem-
bolic events (p 5 0.04).
Results. The overall annual incidence of thromboembolic events
was 2.4% in women and 1.8% in men. On univariate analysis, a
decline in ejection fraction was not associated with thromboem-
bolic risk in women (relative risk [RR] per 10% decrease in
ejection fraction 1.58, 95% confidence interval [CI] 1.10 to 2.26,
p 5 0.01), but not in men. On multivariate analysis, a decline in
ejection fraction remained independently associated with throm-
boembolic risk in women (RR per 10% decrease 1.53, 95% CI 1.06
to 2.20, p 5 0.02), but no relation was demonstrated in men.
Conclusions. In patients with left ventricular systolic dysfunc-
tion and sinus rhythm, the annual incidence of thromboembolic
events is low. Ejection fraction appears to be independently
associated with thromboembolic risk in women, but not in men.
(J Am Coll Cardiol 1997;29:1074–80)
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In an overview of the available data (1), the annual incidence
of thromboembolic events in patients with heart failure ranges
from 0.9 to 5.5 events per 100 patient-years, with the largest
studies reporting an annual incidence of 2.4 to 2.6 events per
100 patient-years (2–9). The risk for clinical embolic compli-
cations has been linked to a low ejection fraction (EF) in
several studies (7,10). The biologic basis supporting this hy-
pothesis relates to abnormal and sluggish flow patterns in
dilated, poorly contracting cardiac chambers, which leads to
mural thrombi as well as venous stasis. This may predispose to
the development of deep venous thrombi and subsequent
pulmonary emboli, as well as peripheral arterial emboli. The
available studies suggest an increased risk of thromboembolic
events in patients with worsening left ventricular systolic
function. However, these data are difficult to interpret because
of the prevalence of atrial fibrillation, an independent risk
factor for thromboembolic events, in the participants with
more severe left ventricular dysfunction. In their review of the
available data related to thromboembolism in heart failure,
Baker and Wright (9) emphasize that there is no published
study that used multivariate analysis techniques to evaluate the
independent effect of ventricular dysfunction on the risk for
arterial thromboembolism. Although it is recognized that
patients with concomitant left ventricular systolic dysfunction
and atrial fibrillation comprise a group at high risk of embolic
complications (12), the incidence of thromboembolic events in
patients with heart failure and sinus rhythm is less clear, as is
the relation of EF to thromboembolic risk.
To address these issues, we conducted a retrospective data
base analysis that consisted of the 6,378 patients entered into
the Studies of Left Ventricular Dysfunction (SOLVD) treat-
ment and prevention trials who, at the time of randomization,
were in sinus rhythm. The purpose of this analysis was twofold:
first, to describe the incidence and etiologic spectrum of
embolic events for a cohort of patients with moderate to severe
systolic dysfunction and sinus rhythm; and second, to study the
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hypothesis that EF is an independent risk factor for embolic
events using multivariate analysis to adjust for potentially
confounding variables that have been identified as indepen-
dent predictors of thromboembolic risk (history of hyperten-
sion, previous stroke and diabetes) (12,13), as well as the use of
antiplatelet or anticoagulant agents.
Methods
Study design. This retrospective data base analysis con-
sisted of 6,378 patients in the SOLVD prevention and treat-
ment trials. These studies were designed to test the hypothesis
that enalapril, an angiotensin-converting enzyme inhibitor,
would reduce mortality in patients with heart failure. There
were 4,228 participants (62%) in the prevention trial, which
consisted of participants with asymptomatic left ventricular
dysfunction, and 2,569 participants (38%) in the treatment
trial, which consisted of participants with symptomatic left
ventricular dysfunction. The entry criteria in both trials re-
quired a documented EF #35%. The EF was measured using
radionuclide angiography (68%), contrast angiography (11%)
or two-dimensional echocardiography (21%), using Simpson’s
rule to yield a calculated value. A more detailed description of
the rationale, design and methodology of the SOLVD trial has
been previously published (14).
Definition of end points. Deaths were classified by the
principal investigators at each clinical site after a blinded
review of the circumstances of each death. The main outcome
variable for the present study was thromboembolic events,
which included fatal or nonfatal cerebrovascular events, pul-
monary emboli and peripheral emboli. Data regarding demo-
graphics, past medical history and current medication profiles
were collected from each participant at the time of random-
ization. Patients with atrial fibrillation on the randomization
electrocardiogram (ECG) were excluded, as were participants
with missing baseline ECG data. This resulted in the exclusion
of 419 participants (280 with missing data from the interpre-
tation of the baseline ECG and 139 with atrial fibrillation). The
final analysis, therefore, consisted of 6,378 participants, includ-
ing 5,457 men (86%) and 921 women (14%).
Statistical analysis. Group comparisons included the two-
sample Student t test for comparison of means, and the
chi-square statistic for comparison of proportions. To satisfy
the assumption of the independence of events, recurrent
thromboembolic events in a participant after randomization
were not included in the analysis. The prognostic significance
of each study covariate on the time until a thromboembolic
event was investigated using univariate and multivariate Cox
proportional hazards models. A two-sided 95% confidence
interval (CI) was constructed around the point estimate of
relative risk (RR) associated with each study covariate. A p
value #0.05 was considered statistically significant.
We tested for evidence of a significant two-way interaction
between EF, and each of the other covariates in the final
multivariate model. There was a significant interaction be-
tween gender and EF on the RR for a thromboembolic event
(p 5 0.04). Therefore, separate analyses were conducted for
each gender. The variables, in addition to EF, that were
studied in both univariate and multivariate analyses in both
genders included: age, EF, history of hypertension, remote
smoking history, diabetes, previous cerebrovascular event, use
of enalapril, antiplatelet monotherapy, anticoagulant mono-
therapy and simultaneous use of antiplatelet and anticoagulant
agents. Medication use was analyzed according to profiles
obtained at the time of randomization. The statistical analyses
were performed using SAS (Statistical Analysis System, version
6.07).
Results
Baseline characteristics. Baseline characteristics are pre-
sented according to gender in Table 1. Women were signifi-
cantly older and had a higher prevalence of diabetes, and a
greater proportion of them had a history of hypertension
compared with their male counterparts. More men used
aspirin monotherapy at baseline and had a remote history of
tobacco use and a history of previous infarction compared with
their female counterparts.
Distribution of embolic events according to gender. Table
2 describes the classification of the 340 first embolic events for
the participants, with an average follow-up of 39.9 months.
There were 278 events in the men for an overall incidence of
Abbreviations and Acronyms
CI 5 confidence interval
ECG 5 electrocardiogram
EF 5 ejection fraction
FS 5 fractional shortening
RR 5 relative risk
SOLVD 5 Studies of Left Ventricular Dysfunction
V-HeFT 5 Veterans Administration Heart Failure Trial
Table 1. Baseline Characteristics of the Participants in the SOLVD
Prevention and Treatment Trials*
Men
(n 5 5,457)
Women
(n 5 921) p Value
Age (yr) 59 6 10 61 6 11 0.0005
Ejection fraction 27 6 6 27 6 6 0.61
History of cerebrovascular accident 344 (6%) 59 (6%) 0.91
Diabetes 997 (18%) 237 (26%) 0.0001
History of hypertension 2,020 (37%) 463 (50%) 0.0001
Aspirin monotherapy 2,579 (47%) 330 (36%) 0.0001
Anticoagulant monotherapy 524 (10%) 77 (8%) 0.23
Aspirin and anticoagulant 124 (2%) 13 (2%) 0.21
Remote tobacco use 4,476 (82%) 541 (59%) 0.0001
Previous myocardial infarction 4,311 (79%) 598 (65%) 0.0001
Enalapril 2,720 (50%) 444 (48%) 0.36
*Excluding patients with atrial fibrillation. Data are presented as mean
value 6 SD or as number (%) of patients. SOLVD 5 Studies of Left Ventricular
Dysfunction.
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1.82 events per 100 participant-years of follow-up, and 62
events in the women for an overall incidence of 2.42 events per
100 participant-years of follow-up. In both genders, most
thromboembolic events were the result of nonfatal cerebrovas-
cular events. The distribution of thromboembolic events ac-
cording to type was similar for men and women, except for a
significantly greater proportion of pulmonary emboli in the
women (24% vs. 14%, p 5 0.01).
Incidence and crude RR stratified by EF quartile. Table 3
presents the overall incidence of thromboembolic events and
unadjusted RR stratified according to EF quartiles. In women,
there is a trend toward an increased incidence of thromboem-
bolic events in the lower EF quartiles, but no such relation is
noted in men. Moreover, women in the lowest two quartiles of
EF demonstrated an incidence of thromboembolic events that
was almost twice that of their male counterparts (3.80% vs.
2.01% for EF 11% to 20%; 4.20% vs. 1.96% for EF #10%).
The unadjusted RR for a thromboembolic event was greater in
women than in men for each quartile, although there was
overlap of the corresponding 95% CIs for each quartile.
Univariate analysis. As demonstrated in Table 4, EF was
significantly related to the risk of a thromboembolic event in
women, but not in men. In women, a 10% decrease in EF was
associated with a 58% increased risk of an embolic events (RR
1.58, 95% CI 1.10 to 2.26, p 5 0.01).
In men, other variables significantly associated with an
increased risk of a thromboembolic event included a history of
hypertension, diabetes and a history of a cerebrovascular
event. Variables associated with a decreased risk of a throm-
boembolic event included use of enalapril and antiplatelet
agents.
In women, univariate analysis demonstrated an increased
risk of a thromboembolic event associated with diabetes.
Similar to men, a decreased risk was associated with antiplate-
let monotherapy for women.
Multivariate analysis. These results are presented in Table
5. On multivariate analysis, a decline in EF remained indepen-
dently associated with an increased risk of thromboembolic
events in women, but no independent association was demon-
strated for men. In women, a 10% decline in EF was associated
with a 53% increased risk of an initial thromboembolic event
during the period of follow-up, which averaged 39.9
participant-months (RR 1.53, 95% CI 1.06 to 2.20, p 5 0.02).
There was no association between EF and thromboembolic
risk in men (RR 1.08, 95% CI 0.89 to 1.31, p 5 0.42).
In men, other variables independently associated with the
risk of a thromboembolic event included a 32% increased risk
with a history of hypertension, a 64% increased risk with
diabetes and a 131% increased risk in participants with a
previous cerebrovascular event. The use of enalapril was
associated with a 26% risk reduction, compared with partici-
pants receiving placebo. The use of antiplatelet agents at
baseline was associated with a 23% risk reduction, although of
borderline statistical significance (RR 0.77, 95% CI 0.59 to
1.00, p 5 0.06).
In women, other variables associated with the risk of
thromboembolic events on multivariate analysis included dia-
betes, which was associated with a 113% increased risk for
thromboembolism, and antiplatelet monotherapy at baseline,
which was associated with a 53% reduction in the risk of
thromboembolism, compared with those not using antiplatelet
agents at baseline.
Table 2. Classification of Embolic Events by Gender
Stroke
[no. (% CVA)]
Pulmonary
Embolism
[no. (% PE)]
Peripheral
Embolism
[no. (% PerE)]
Men (n 5 5,457)
Total events
Fatal 30 (16) 15 (37) 4 (8)
Nonfatal 160 (84) 25 (63) 44 (92)
Total TEE 190 (68) 40 (14)* 48 (18)
Women (n 5 921)
Total events
Fatal 5 (14) 6 (40) 1 (9)
Nonfatal 31 (86) 9 (60) 10 (91)
Total TEE 36 (58) 15 (24)* 11 (18)
*p 5 0.01. CVA 5 cerebrovascular accident; PE 5 pulmonary embolism;
PerE 5 peripheral embolism; TEE 5 thromboembolic events.
Table 3. Incidence and Crude Relative Risk of Thromboembolic Events According to Gender and
Ejection Fraction Quartile
EF
Men (n 5 5,457) Women (n 5 921)
No. (%) Incidence* RR (95% CI)† No. (%) Incidence RR (95% CI)
$ 30% 1,892 (35) 1.70 1.00 335 (36) 1.78 1.00
21–30% 2,590 (47) 1.83 1.08 (0.83–1.41) 422 (46) 2.41 1.35 (0.74–2.47)
11–20% 928 (17) 2.01 1.21 (0.86–1.70) 154 (17) 3.80 2.17 (1.10–4.30)
#10% 47 (1) 1.96 1.21 (0.30–4.92) 10 (1) 4.20 2.43 (0.32–18.26)
*The incidence is for the first-time events for a participant in either Studies of Left Ventricular Dysfunction
Prevention or Treatment Trial. Recurrent events in an individual are not counted. The incidence is expressed as the
number of thromboembolic events (combined end points of cerebrovascular accident, pulmonary embolism or peripheral
arterial embolism) per 100 patient-years of follow-up. Participants with an ejection fraction $30% are chosen as the
reference group in calculating the crude relative risk. Patients with atrial fibrillation are excluded. †Age-adjusted relative
risk (RR) and two-sided 95% confidence interval (CI). EF 5 ejection fraction.
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Exclusion of pulmonary emboli. The only significant dif-
ference between the genders in the distribution of a specific
type of embolic event was the statistically significant greater
proportion of events caused by pulmonary emboli in the
women (24% vs. 14%, p 5 0.01). When pulmonary embolism
was excluded, there were 238 events in men and 48 events in
women that were attributed to a cerebrovascular event or
peripheral embolism.
Using these events as our definition of a thromboembolic
event, identical univariate and multivariate analyses were
conducted in the genders, and the results of the multivariate
analysis are presented in Table 6. On univariate analysis, EF
was significantly associated with the risk of thromboembolic
events in women, but not in men. On multivariate analysis,
there was a trend suggesting that a lower EF was associated
with an increased thromboembolic risk in women (RR per
10% decrease in EF 1.47, 95% CI 0.97 to 2.23, p 5 0.07), but
in men there was no demonstration of an independent associ-
ation between EF and thromboembolic risk (RR per 10%
decrease in EF 0.99, 95% CI 0.81 to 1.22, p 5 0.95).
Discussion
Study findings. This is the first large data base study of
patients with heart failure that attempts to study whether EF is
independently associated with thromboembolic risk for pa-
tients in sinus rhythm with moderate to severe left ventricular
systolic dysfunction. The analysis demonstrates that the overall
annual incidence of thromboembolic events is low in both
genders (2.4% in men and 1.8% in women). Also, it appears
that in women, but interestingly not in men, EF was indepen-
dently associated with thromboembolic risk.
Gender differences in the association of EF and thrombo-
embolic risk. The finding of a significant interaction between
gender and EF on thromboembolic risk was unexpected.
Although the reasons for gender differences in the association
of EF and the risk of a thromboembolic event cannot be
determined with certainty from this study, several possible
explanations are considered.
The only significant difference between the genders in the
distribution of thromboembolic events was a greater propor-
Table 4. Univariate Analysis: Relative Risk of a Thromboembolic Event According to Gender
Men (n 5 5,457) Women (n 5 921)
RR (95% CI) p Value RR (95% CI) p Value
Age, per decade 1.0006 (1.00–1.001) 0.0003 1.07 (0.84–1.36) 0.60
EF, per 10% decrease 1.26 (1.11–1.42) 0.36 1.58 (1.10–2.26) 0.01
History of hypertension 1.54 (1.22–1.95) 0.0003 1.06 (0.64–1.75) 0.82
Smoking history, yes/no 0.82 (0.61–1.10) 0.17 1.39 (0.82–2.35) 0.22
Diabetes, yes/no 1.86 (1.43–2.43) 0.0001 1.82 (1.08–3.06) 0.02
Previous CVA 2.58 (1.82–3.66) 0.0001 1.71 (0.74–3.98) 0.21
Previous MI 0.71 (0.54–0.93) 0.01 0.69 (0.42–1.14) 0.15
Enalapril vs. placebo 0.73 (0.58–0.93) 0.01 0.81 (0.49–1.33) 0.40
Antiplatelet monotherapy 0.74 (0.58–0.94) 0.01 0.45 (0.24–0.84) 0.01
Anticoagulant monotherapy 1.14 (0.79–1.66) 0.49 1.51 (0.72–3.18) 0.27
Antiplatelet and anticoagulant* 1.57 (0.83–2.95) 0.16 2.16 (0.53–8.83) 0.29
*Patients receiving concurrent therapy with these agents at the time of randomization. CI 5 confidence interval;
CVA 5 cerebrovascular accident; EF 5 ejection fraction; MI 5 myocardial infarction; RR 5 relative risk.
Table 5. Multivariate Analysis: Relative Risk of Thromboembolic Event According to Gender
Men (n 5 5,457) Women (n 5 921)
RR (95% CI) p Value RR (95% CI) p Value
Age, per decade 1.19 (1.05–1.35) 0.006 1.16 (0.89–1.49) 0.27
EF, per 10% decrease 1.08 (0.89–1.31) 0.42 1.53 (1.06–2.20) 0.02
History of hypertension 1.32 (1.04–1.69) 0.02 0.93 (0.55–1.56) 0.77
Smoking history, yes/no 0.90 (0.67–1.21) 0.49 1.71 (0.99–2.98) 0.06
Diabetes, yes/no 1.64 (1.25–2.14) 0.0003 2.13 (1.22–3.71) 0.008
Previous CVA 2.31 (1.61–3.31) 0.0001 1.66 (0.69–3.94) 0.26
Previous MI 0.79 (0.60–1.05) 0.10 0.81 (0.47–1.38) 0.43
Enalapril vs. placebo 0.74 (0.58–0.94) 0.01 0.77 (0.46–1.29) 0.32
Antiplatelet monotherapy 0.77 (0.59–1.00) 0.06 0.47 (0.24–0.92) 0.03
Anticoagulant monotherapy 0.97 (0.65–1.44) 0.87 1.24 (0.56–2.71) 0.60
Antiplatelet and anticoagulant* 1.38 (0.72–2.63) 0.33 2.20 (0.52–9.31) 0.28
*Patients receiving concurrent therapy with these agents at the time of randomization. Abbreviations as in Table 4.
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tion of pulmonary emboli in the women (24%) compared with
the men (14%) (p 5 0.01). Therefore, we considered the
possibility that the gender differences might be statistically
driven by an especially strong relation in women between a
declining EF and risk of pulmonary emboli. Reasons for such
a difference might include a greater degree of functional
impairment limiting physical activity in women compared with
men with a similar EF. The resulting inactivity might increase
venous stasis, the development of deep venous thrombi and
subsequent emboli to the pulmonary circulation. Therefore, we
conducted a multivariate analysis adjusting for the same vari-
ables but excluding pulmonary emboli from our definition of a
thromboembolic event. Although there was a reduction in the
strength of the statistical association between EF and throm-
boembolic risk in women (p 5 0.07), a trend persisted in the
women, demonstrating an increased risk of thromboembolic
events as EF fell, but again there was no association in men.
The reduction in statistical significance in women (p 5 0.07)
may be the result of the reduced statistical power resulting
from fewer overall events.
We included all cerebrovascular events in our definition of
thromboembolic events, and we recognize that not all the
cerebrovascular events were likely to be caused by a cardio-
embolic event. The possibility exists that there were gender
differences in the proportion of cerebrovascular events that
were the result of comorbid atherosclerotic disease or intrace-
rebral hemorrhage, rather than cardiac emboli. Because these
cerebrovascular events are not expected to be related to EF, a
greater proportion of such events in men might make it difficult
to statistically demonstrate a relation between EF and throm-
boembolic risk. The multivariate analysis adjusted for some of
the baseline differences in the clinical variables, which were
each previously demonstrated to independently predict throm-
boembolic risk (12,13). Nonetheless, we cannot exclude the
possibility of confounding from incomplete adjustment in
important baseline differences between the genders, as well as
residual confounding from the variables included in the mul-
tivariate model.
Although this is a retrospective analysis, the possibility
exists that there may be important physiologic gender differ-
ences in the production of thromboembolism in heart failure.
Important gender differences might exist in the clotting system
and fibrinolytic system, the biology of the endothelium lining
the ventricle or the influence of hormonal differences on the
defense mechanisms against intraventricular or intravascular
thrombosis.
Comparison with other studies. This is the first study
attempting to use multivariate analysis techniques to study the
independent association between ventricular dysfunction and
the risk of thromboembolism. Kyrle et al. (15) studied 38
patients with dilated cardiomyopathy and classified severity of
left ventricular dysfunction according to echocardiographic
fractional shortening (FS). Before the initiation of anticoagu-
lation, the proportion experiencing an arterial or pulmonary
embolism was 20% in those with mild dysfunction (FS 0.20 to
0.28), 47% in those with moderate dysfunction (FS 0.1 to 0.2)
and 67% in the severe group (FS ,0.1). There was no
information in this study about the presence or absence of
atrial fibrillation. Two of the largest trials, the Veterans
Administration Heart Failure Trials (V-HeFT) I and II (7),
demonstrated an incidence of thromboembolic events—
defined to include stroke, pulmonary emboli and peripheral
emboli—of 2.7 per 100 patient-years in V-HeFT I and 2.1 per
100 patient-years in V-HeFT II. Patients experiencing a throm-
boembolic event had a lower EF compared with patients who
did not (26.3% vs. 29.6%), but the difference was not statisti-
cally significant. This report did report separate incidence data
for the participants with and without atrial fibrillation, but the
results were paradoxic. For example, the incidence of throm-
boembolism in those participants with atrial fibrillation (3.8%)
was less than that of those without it (5.6%). These results
might be explained by differences in the use of anticoagulant
agents as well as other baseline differences in the patients with
atrial fibrillation. Segal et al. (16) reported a higher incidence
of systemic emboli in patients with minimal to mild cardiac
enlargement on chest roentgenogram (11%) compared with
Table 6. Multivariate Analysis: Relative Risk of Thromboembolic Events by Gender After Exclusion
of Pulmonary Emboli
Men (n 5 5,457) Women (n 5 958)
RR (95% CI) p Value RR (95% CI) p Value
Age, per decade 1.29 (1.12–1.48) 0.007 1.07 (0.80–1.42) 0.27
EF, per 10% decrease 0.99 (0.81–1.22) 0.95 1.47 (0.97–2.23) 0.07
History of hypertension 1.30 (1.0–1.69) 0.05 1.04 (0.57–1.88) 0.90
Smoking history, yes/no 0.93 (0.68–1.28) 0.65 2.42 (1.24–4.72) 0.01
Diabetes, yes/no 1.71 (1.29–2.28) 0.0002 2.32 (1.24–4.34) 0.009
Previous CVA 2.58 (1.78–3.76) 0.0001 2.34 (0.96–5.71) 0.06
Previous MI 0.77 (0.57–1.03) 0.08 0.75 (0.41–1.36) 0.34
Enalapril vs. placebo 0.80 (0.62–1.04) 0.09 0.67 (0.38–1.21) 0.18
Antiplatelet monotherapy 0.71 (0.53–0.94) 0.02 0.37 (0.18–0.84) 0.84
Anticoagulant monotherapy 0.92 (0.59–1.42) 0.69 1.09 (0.44–2.71) 0.84
Antiplatelet and anticoagulant* 1.53 (0.80–2.93) 0.21 2.89 (0.67–12.39) 0.15
*Patients receiving concurrent therapy with these agents at the time of randomization. Abbreviations as in Table 4.
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those with moderate to severe cardiac enlargement (16%), but
the difference did not reach statistical significance. Yokota et
al. (17) found that patients with mural thrombi had a lower EF
(13.1%) than those without them (17.9%).
Study limitations. The limitations of this study must be
emphasized. The SOLVD trials were not designed to deter-
mine the incidence of thromboembolic complications in heart
failure. This is a retrospective analysis of the large data base
assembled from these studies. Criteria for the diagnosis of
thromboembolic events were not established by protocol, and
the events that were reported did not undergo central review
for possible reclassification. Despite these limitations, we do
not believe that there was significant underreporting of throm-
boembolic events, nor that there were important differences
among the participating institutions in the diagnosis of stroke,
transient ischemic attacks or pulmonary and peripheral em-
boli.
Medication use was analyzed based on reported regular use
at the time of randomization, and it is likely that there were
changes in some patients during the course of the studies.
Treatment with antiplatelet or anticoagulant agents was not
randomized or blinded, and a target prothrombin or interna-
tional normalized ratio was not specified. Although we ex-
cluded participants with atrial fibrillation, this was assessed at
baseline, and it is likely that some participants developed atrial
fibrillation during the trials. There was a greater prevalence of
hypertension in women, which can lead to the development of
atrial fibrillation, so it is possible that a greater proportion of
women might have subsequently developed atrial fibrillation
compared with their male counterparts.
The presence of residual confounding from variables we
attempted to adjust for is likely because some of these baseline
characteristics were not assessed using a precise classification
scheme. For example, we lacked information regarding the
type and duration of diabetes, the duration and intensity of
previous smoking habits, the duration and severity of previous
hypertension, as well as the degree of anticoagulation achieved
in the patients taking anticoagulant agents.
Clinical implications. These data suggest that in patients
with moderate to severe left ventricular dysfunction the inci-
dence of thromboembolic events is low. Also, in women, but
not in men, the severity of left ventricular dysfunction, quan-
tified by the calculated EF, is independently associated with
the risk for thromboembolic events. The low overall incidence
of events raises the clinically important question of whether
anticoagulation to prevent thromboembolic complications in
these patients presents a favorable risk/benefit balance. The
risk of serious bleeding among participants in the clinical trials
assessing the efficacy of anticoagulation in atrial fibrillation was
less than 1% per year (12); however, the risk may be greater in
a more generalized outpatient population (18).
The annual incidence of thromboembolic events demon-
strated by the women in the lowest two quartiles of EF (3.8%
for EF 11% to 20%, 4.2% for EF #10%) approaches the
estimated annual incidence of embolic complications in pa-
tients with atrial fibrillation, which is estimated to be 5%
(12,19,20), and may identify a group with a more favorable
risk/benefit ratio. Moreover, the efficacy of anticoagulation in
heart failure to prevent thromboembolic events has not been
demonstrated in any randomized, controlled clinical trial.
Also, these data suggest that there may be important gender
differences in the pathophysiologic mechanisms relating ven-
tricular dysfunction to the risk of thromboembolism within the
heart failure population, the specific nature of which remains
to be further elucidated.
Conclusions. The overall incidence of thromboembolic
events in patients with moderate to severe left ventricular
dysfunction and sinus rhythm is low. Moreover, the degree of
left ventricular dysfunction as quantified by EF appears to be
independently associated with thromboembolic risk in women,
but not in men. These data suggest the possible existence of
physiologic gender differences in the production of thrombo-
embolism in patients with significant left ventricular dysfunc-
tion.
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